Table 39: Clinical evidence profile: Comparison 2. Ciprofloxacin versus placebo

Quality assessment							No of patients		Effect			
No of studies	**Design**	**Risk of bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Ciprofloxacin**	**Placebo**	**Relative (95% CI)**	**Absolute**	**Quality**	**Importance**
Lung function: FEV_1												
Not reported												CRITICAL
Number of people with 1 or more exacerbations												
NMA outcome												CRITICAL
Nutritional status: weight (follow-up 6 to 12 months; measured with: kg; Better indicated by higher values)												
1 (Sheldon 1993)	randomised trials	very serious [1]	no serious inconsistency	no serious indirectness	serious[2]	none	15	16	-	MD 4.4 higher (3.7 lower to 12.5 higher)	VERY LOW	IMPORTANT
Minor adverse events: gastrointestinal (follow-up 12 months)												
1 (Sheldon 1993)	randomised trials	very serious [3]	no serious inconsistency	no serious indirectness	very serious[4]	none	2/20 (10%)	0/20 (0%)	RR 5 (0.26 to 98)	-	VERY LOW	IMPORTANT
Mortality (follow-up 12 months)												
1 (Sheldon 1993)	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	very serious[5]	none	1/20 (5%)	1/20 (5%)	RR 1 (0.07 to 14.9)	0 fewer per 1000 (from 47 fewer to 695 more)	LOW	IMPORTANT
Emergence of resistant organisms - isolation of resistant strains of *P aeruginosa* (follow-up 12 months)												

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ciprofloxacin	Placebo	Relative (95% CI)	Absolute		
1 (Sheldon 1993)	randomised trials	very serious [1]	no serious inconsistency	no serious indirectness	serious[2]	none	10/15 (66.7%)	5/16 (31.3 %)	RR 2.13 (0.95 to 4.8)	353 more per 1000 (from 16 fewer to 1000 more)	VERY LOW	IMPORTANT
Emergence of resistant organisms - isolation of resistant strains of *S aureus* (follow-up 12 months)												
1 (Sheldon 1993)	randomised trials	very serious [1]	no serious inconsistency	no serious indirectness	very serious[4]	none	4/15 (26.7%)	6/16 (37.5 %)	RR 0.71 (0.25 to 2.03)	109 fewer per 1000 (from 281 fewer to 386 more)	VERY LOW	IMPORTANT

Abbreviations: CI: confidence interval; FEV_1: forced expiratory volume in 1 second; MD: mean difference; RR: risk ratio
1 The quality of the evidence was downgraded by 2 due to unclear blinding and reporting and high loss to follow-up
2 The quality of the evidence was downgraded by 1 as the 95% CI crossed 1 default MID
3 The quality of the evidence was downgraded by 1 due to unclear blinding and reporting
4 The quality of the evidence was downgraded by 2 as the 95% CI crossed 2 default MIDs
5 The quality of the evidence was downgraded by 2 as the 95% CI crossed the line of null effect, and the CI is very wide (trial underpowered to detect a difference)